Brand and Other Names:Tracrium
Dosing & Uses
Dosage Forms & Strengths
Endotracheal Intubation, Mechanical Ventilation
Calculate dose based on ideal body weight
Continuous infusion: 0.005-0.01 mg/kg/min IV (ranges from 0.002-0.015 mg/kg/min) OR
0.2-0.4 mg/kg IVP if following succinylcholine for intubation
Reduce dose if given with general anesthetics that potentiate its activity (eg, isoflurane)
Other Indications & Uses
Skeletal muscle relaxation during surgery
Dosage Forms & Strengths
Serious - Use Alternative
Significant - Monitor Closely
Skin flush (5%)
Increased bronchial secretions (0.2%)
Erythema at injection site
Changes in heart rate (0.6-2.1%)
Mean arterial pressure (1.9%)
Diastolic arterial pressure changes
Systemic vascular resistance changes
Cardiac index changes
Cardiac output changes
Cardiac arrest (0.001%)
CAUTION: adequate ventilatory support mandatory, may experience resistance with >25% TBSA burns, may experience incr sensitivity with electrolyte disorders (hyperMg, hypoK, hypoCa)
Lack of ventilatory support, neuromuscular disease
Additive/synergistic effects if administered with or following an opioid, sedative or anesthetic agent
Closely monitor pts w/: bronchogenic carcinoma, dehydration, electrolyte imbalance, hypotension, hypothermia, myasthenia gravis, pulmonary disease
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Alpha: 2-3.4 min
Beta: averages 20 min
Onset: 2-2.5 min; may be slightly delayed in patients with renal failure
Duration: 20-35 min
Protein Bound: 82%
Vd: 160 mL/kg (range: 120-188 mL/kg)
Metabolism: to laudanoside by non-enzymatic cleavage independent of hepatic/renal function
Excretion: principally in urine & also in feces via biliary elimination
Mechanism of Action
Non-depolarizing skeletal muscle relaxant; cholinergic receptor antagonist
Solution: D5/NS, D5W(?), NS(?)
Additive: bretylium, cimetidine, ciprofloxacin, dobutamine, dopamine, esmolol, gentamicin, isoproterenol, lidocaine, morphine, KCl, procainamide, vancomycin
Syringe: alfentanil, fentanyl, midazolam, sufentanil
Y-site: amiodarone, cefazolin, cefuroxime, cimetidine, clarithromycin, dobutamine, dopamine, epinephrine, esmolol, etomidate, fenoldopam, fentanyl, gentamicin, heparin, Hextend, hydrocortisone, isoproterenol, lorazepam, midazolam, milrinone, morphine, nitroglycerin, ranitidine, Na nitroprusside, trimethoprim/sulfamethoxazole, vancomycin
Additive: aminophylline, cefazolin, heparin, quinidine gluconate, ranitidine, sodium nitroprusside
Syringe: alkaline solutions
Y-site: diazepam, propofol(?), thiopental
Add to an empty Viaflex bag & infuse undiluted (10 mg/mL); however, if necessary, may be diluted in D5W, NS or dextrose-saline combinations
Dilution in LR not recommended
Not for IM injection due to tissue irritation
May be given undiluted as bolus injection
Administration via infusion requires use of an infusion pump
Use infusion solutions within 24 hr of preparation
Unstable in alkaline solutions
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs